Emerging reports suggest that inhibition of TIGIT(T cell immunoreceptor with Ig and ITIM domains) has shown promise in enhancing anti-tumor immunity by complementing the PD-L1/PD-1 axis. This evidence concerns the gene TIGIT and neoplasm.